Skip to main content

Posts tagged with "Cardiovascular Disease"

  • Cardiovascular Disease

    PCSK9 In the Details

    The PCSK9 inhibitors are a class of drugs from which great things are expected. The first ones hitting the market are antibodies, and blocking this enzyme, which is involved in cholesterol homeostasis, clearly has major effects on circulating LDL levels. There are a lot of approaches to going after this target, in the lab, the… Read More
  • Cardiovascular Disease

    Clinical Trials: Getting Much Worse, or Much Better?

    Here’s a very interesting overview of the clinical trials funded (55 total) by the National Heart, Lung, and Blood Institute (NHLBI) over the years 1970-2012. Breaking them into pre-2000 and post-2000 shows something dramatic: in the 30 older trials, 57% of them reported a positive, beneficial outcome. Of the 25 newer ones, only 8% came back… Read More
  • Cardiovascular Disease

    PCSK9 at the FDA

    So an FDA advisory committee met yesterday to consider the PCSK9 antibody from Regeneron and Sanofi, and today it’s the turn of Amgen’s candidate. These, as anyone with even a passing interest in cardiovascular medicine will know, are potential gigantic blockbusters and advances in the field, promising to lower LDL across a huge swath o… Read More
  • Cardiovascular Disease

    Defibrillating Dalcetrapib

    In 2012, Roche halted development of their CETP inhibitor dalcetrapib, part of what (so far) has been a grim chapter in cardiovascular drug development. At the time, this was put down to lack of efficacy, rather than the bad effects seen with Pfizer’s torcetrapib, news that did nothing to cheer up the CETP research community. Read More
  • Cardiovascular Disease

    How Not to Handle Your Clinical Data

    We turn now to Orexigen, one of the small companies trying to make headway in the obesity market. Earlier this year, a patent application from them published, claiming that their drug (Contrave, a sustained release formulation combining the known drugs naltrexone and bupropion) had cardiovascular benefits above and beyond its weight-loss effects. P… Read More
  • Cardiovascular Disease

    Amgen Claims It All

    There’s plenty of excitement about PCSK9, the latest LDL-lowering pathway to make it deep into the clinic. You can tell that companies (and investors) have high hopes for it, since it’s heading right into a market that’s dominated by generic statins. The optimism may well be justified – for example, Sanofi and Regeneron rece… Read More
  • Cardiovascular Disease

    Vytorin Actually Works

    The data from the IMPROVE-IT trial on cardiovascular outcomes for Vytorin have been released. And the combination met the primary endpoint: fewer heart attacks and strokes compared to those already on statin therapy alone. Matthew Herper has an excellent roundup of the results and their context. The effect is real, but it’s not gigantic, eith… Read More
  • Cardiovascular Disease

    Remember Vytorin? The Data Are Finally Coming.

    If you follow cardiovascular therapies, you’ll no doubt have seen that a bit of information has come out on Merck’s long, long, long-running IMPROVE-IT trial. That is the massive outcomes study for Vytorin, the combination of ezetimibe (the Schering-Plough cholesterol absorption inhibitor) and simvastatin (Merck’s early statin dru… Read More
  • Business and Markets

    A VC Firm Touts Its Successes – And Its Failures

    Here’s what sounds like a good idea from VC firm Index Ventures, from the latest issue of BioCentury (same one I referenced the other day). Like many others in the biopharma venture capital world, they’re trying to run the “killer experiment” as soon as possible, to see which ideas for new companies look solid. Unlike… Read More
  • "Me Too" Drugs

    Novartis Impresses Where Others Have Failed

    There is some good news from the clinic today. Novartis reported data on LCZ696, a combination therapy for congestive heart failure, and the results have really grabbed a lot of attention. (The trial had been stopped early back in March, so the news was expected to be good). This is a combo of the angiotensin… Read More